AIMS: To determine risk for central nervous system/autonomic nervous system (CNS/ANS) signs following in utero cocaine and opiate exposure. METHODS: A multisite study was designed to determine outcomes of in utero cocaine and opiate exposure. A total of 11 811 maternal/infant dyads were enrolled. Drug exposed (EXP) infants were identified by maternal self report of cocaine or opiate use or by meconium testing. Of 1185 EXP, meconium analysis confirmed exposure in 717 to cocaine (CO) only, 100 to opiates (OP), and 92 to opiates plus cocaine (OP+CO); 276 had insufficient or no meconium to confirm maternal self report. Negative exposure history was confirmed in 7442 by meconium analysis and unconfirmed in 3184. Examiners masked to exposure status, assessed each enrolled infant. Using generalised estimating equations, adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated for manifesting a constellation of CNS/ANS outcomes and for each sign associated with cocaine and opiate exposure. RESULTS: Prevalence of CNS/ANS signs was low in CO, and highest in OP+CO. Signs were significantly related to one another. After controlling for confounders, CO was associated with increased risk of manifesting a constellation of CNS/ANS outcomes, OR (95% CI): 1.7 (1.2 to 2.2), independent of OP effect, OR (95% CI): 2.8 (2.1 to 3.7). OP+CO had additive effects, OR (95% CI): 4.8 (2.9 to 7.9). Smoking also increased the risk for the constellation of CNS/ANS signs, OR (95% CI) of 1.3 (1.04 to 1.55) and 1.4 (1.2 to 1.6), respectively, for use of less than half a pack per day and half a pack per day or more. CONCLUSION: Cocaine or opiate exposure increases the risk for manifesting a constellation of CNS/ANS outcomes.
AIMS: To determine risk for central nervous system/autonomic nervous system (CNS/ANS) signs following in utero cocaine and opiate exposure. METHODS: A multisite study was designed to determine outcomes of in utero cocaine and opiate exposure. A total of 11 811 maternal/infant dyads were enrolled. Drug exposed (EXP) infants were identified by maternal self report of cocaine or opiate use or by meconium testing. Of 1185 EXP, meconium analysis confirmed exposure in 717 to cocaine (CO) only, 100 to opiates (OP), and 92 to opiates plus cocaine (OP+CO); 276 had insufficient or no meconium to confirm maternal self report. Negative exposure history was confirmed in 7442 by meconium analysis and unconfirmed in 3184. Examiners masked to exposure status, assessed each enrolled infant. Using generalised estimating equations, adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated for manifesting a constellation of CNS/ANS outcomes and for each sign associated with cocaine and opiate exposure. RESULTS: Prevalence of CNS/ANS signs was low in CO, and highest in OP+CO. Signs were significantly related to one another. After controlling for confounders, CO was associated with increased risk of manifesting a constellation of CNS/ANS outcomes, OR (95% CI): 1.7 (1.2 to 2.2), independent of OP effect, OR (95% CI): 2.8 (2.1 to 3.7). OP+CO had additive effects, OR (95% CI): 4.8 (2.9 to 7.9). Smoking also increased the risk for the constellation of CNS/ANS signs, OR (95% CI) of 1.3 (1.04 to 1.55) and 1.4 (1.2 to 1.6), respectively, for use of less than half a pack per day and half a pack per day or more. CONCLUSION:Cocaine or opiate exposure increases the risk for manifesting a constellation of CNS/ANS outcomes.
Authors: Charles R Bauer; Seetha Shankaran; Henrietta S Bada; Barry Lester; Linda L Wright; Heidi Krause-Steinrauf; Vincent L Smeriglio; Loretta P Finnegan; Penelope L Maza; Joel Verter Journal: Am J Obstet Gynecol Date: 2002-03 Impact factor: 8.661
Authors: Charles R Bauer; John Langer; Brittany Lambert-Brown; Seetha Shankaran; Henrietta S Bada; Barry Lester; Lynn L Lagasse; Toni Whitaker; Jane Hammond Journal: J Perinatol Date: 2020-05-22 Impact factor: 2.521
Authors: Stephen J Sheinkopf; Elena J Tenenbaum; Daniel S Messinger; Cynthia L Miller-Loncar; Ed Tronick; Linda L Lagasse; Seetha Shankaran; Henrietta Bada; Charles Bauer; Toni Whitaker; Jane Hammond; Barry M Lester Journal: Dev Sci Date: 2016-10-23
Authors: Seetha Shankaran; Barry M Lester; Abhik Das; Charles R Bauer; Henrietta S Bada; Linda Lagasse; Rosemary Higgins Journal: Semin Fetal Neonatal Med Date: 2007-02-20 Impact factor: 3.926
Authors: Abhik Das; Jon Tyson; Claudia Pedroza; Barbara Schmidt; Marie Gantz; Dennis Wallace; William E Truog; Rosemary D Higgins Journal: Semin Perinatol Date: 2016-06-22 Impact factor: 3.300
Authors: Matthew Todd Hambleton; Eric W Reynolds; Thitinart Sithisarn; Stuart J Traxel; Abhijit R Patwardhan; Timothy N Crawford; Marta S Mendiondo; Henrietta S Bada Journal: Front Pediatr Date: 2013-10-17 Impact factor: 3.418
Authors: Enrique Gomez Pomar; Loretta P Finnegan; Lori Devlin; Henrietta Bada; Vanessa A Concina; Katrina T Ibonia; Philip M Westgate Journal: BMJ Open Date: 2017-09-27 Impact factor: 2.692